Physician profile
Stanley S Yang
NPI 1659427862
$3,368.93
in general payments reported to CMS, 2019-2025
25 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $471 · 2021: $495 · 2022: $200 · 2023: $408 · 2024: $691 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $703.47 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $623.10 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $513.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $347.16 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $334.76 | 2022-2025 | |
| Glaxosmithkline, LLC. | $149.90 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Vertex Pharmaceuticals Incorporated | $109.39 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.41 | 2019-2022 | |
| Exact Sciences Corporation | $56.27 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $52.70 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.78 | 2020-2024 | Trulance, Xifaxan |
| Pfizer INC. | $43.76 | 2021 | |
| Vanda Pharmaceuticals INC. | $43.57 | 2020-2021 | |
| Amarin Pharma, INC. | $39.03 | 2020 | |
| Sanofi Pasteur INC. | $30.24 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.00 | 2023 | |
| Abbvie INC. | $26.40 | 2025 | |
| Abbott Laboratories | $20.80 | 2021 | |
| Corium, LLC | $20.51 | 2024 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $18.54 | 2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $16.30 | 2023 | Qelbree |
| Genentech USA, INC. | $13.42 | 2019 | |
| Horizon Therapeutics Plc | $12.74 | 2019 | |
| Phadia US INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.